SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Down 91.1% in June

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the recipient of a significant decline in short interest in the month of June. As of June 30th, there was short interest totaling 610 shares, a decline of 91.1% from the June 15th total of 6,872 shares. Based on an average daily volume of 7,586 shares, the days-to-cover ratio is currently 0.1 days.

SAB Biotherapeutics Trading Down 20.8%

Shares of SAB Biotherapeutics stock traded down $0.00 during trading hours on Friday, reaching $0.01. The company’s stock had a trading volume of 160,556 shares, compared to its average volume of 48,969. The company’s 50 day simple moving average is $0.02 and its 200 day simple moving average is $0.03. SAB Biotherapeutics has a one year low of $0.01 and a one year high of $0.18.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.

The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.